By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Expert Rev Mol Diagn. 2008;8(4):417-434. The College of American Pathologists (CAP) and ASCO recently organized an expert panel, which conducted a systematic review of the literature and developed ...

Currently, each newly diagnosed breast cancer case is assessed for HER2 status, either by IHC or ISH, and although some experts would like the use of ISH as the primary approach in HER2 testing ...